Tegaserod

CAS No. 145158-71-0

Tegaserod( —— )

Catalog No. M35455 CAS No. 145158-71-0

Tegaserod is an orally available 5-HT4R agonist and 5-HT2B receptor antagonist with inhibitory effects on various 5-hydroxytryptamine receptors. Tegaserod has antitumor activity and is used in the treatment of irritable bowel syndrome (IBS).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tegaserod
  • Note
    Research use only, not for human use.
  • Brief Description
    Tegaserod is an orally available 5-HT4R agonist and 5-HT2B receptor antagonist with inhibitory effects on various 5-hydroxytryptamine receptors. Tegaserod has antitumor activity and is used in the treatment of irritable bowel syndrome (IBS).
  • Description
    Tegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT4R) agonist and a 5-HT2B receptor antagonist. Tegaserod has pKis of 7.5, 8.4 and 7.0 for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research.
  • In Vitro
    Apoptosis Analysis Cell Line:A375, RPMI-7951 (RPMI), SH4, B16F10, MeWo and MEL-JUSO Concentration:3, 5 μM Incubation Time:24, 48, 72 hResult:There was a significant time and dose-dependent increase in apoptosis in all cell lines.Western Blot Analysis Cell Line:RPMI, SH4 and B16F10 cells Concentration:3, 5 μM Incubation Time:8 or 18?h Result:Decreased phosphorylation of the kinase directly upstream of S6, p70 S6 at Thr421/Ser424.
  • In Vivo
    Animal Model:C57BL/6?J mice were subcutaneously injected with B16F10 cells Dosage:5?mg/kg Administration:Administered intraperitoneally (i.p.) daily for five consecutive days Result:Treatment significantly decreased tumor growth and resulted in only slight decreases in weight following treatment.Animal Model:Female C57BLKS/J db/db miceDosage:0.1, 0.5, 1.0, 2.0 mg/kg Administration:IP 15 min prior to gastric loading Result: Produced a dramatic decrease in the fraction of the meal remaining in the stomach for doses as low as 0.1 mg/kg (0.1 mg/kg). Accelerated gastric emptying, with a reduction of nearly 80% in the fraction remaining at 30 min (P < 0.0001) (0.1 mg/kg).Induced a significant decrease in the gastric emptying rate as the amount of the meal remaining at 30 min was significantly greater (2.0 mg/kg).Resulted in inhibition of tegaserod-induced increased gastric emptying (0.1 mg/kg).
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    5-HT Receptor
  • Recptor
    5-HT Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    145158-71-0
  • Formula Weight
    301.39
  • Molecular Formula
    C16H23N5O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (165.90 mM; Ultrasonic )
  • SMILES
    N=C(NN=CC1=CNC=2C=CC(OC)=CC12)NCCCCC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wei Liu, et al. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. J Exp Clin Cancer Res. 2020 Feb 21;39(1):38.?
molnova catalog
related products
  • EMD-281014

    EMD-281014 (Pruvanserin, LSN2411347, LY-2422347) is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM.

  • BF-1

    BF-1 is a novel selective 5-HT2 receptor antagonist that acts by blocking neurogenic dural plasma protein extravasation induced by mCPP or BW723C86.BF-1 is used in the study of migraine.

  • Landipirdine

    A novel 5-HT receptor antagonist for the treatment of Parkinson's disease.